Autologous Dermal Fibroblast
|Basic Research||Non-clinical||Phase 1||Phase 2||Phase 3||Approval|
Marketing (conditional approval) and phase 3 clinical trial in progress
The efficacy evaluation of the phase 1/2 clinical trial revealed a significant improvement effect (improvement of 2 or more stages) in 50% (11 out of 22) subjects 3 months after the administration of CureSkin Inj. (3 times every 2 weeks). The result was also verified in the 3D stereoimage optical topometry (SOT) measurement.